MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy

BACKGROUND: Tamoxifen (TAM) and fulvestrant (FUL) are the major drugs for patients with estrogen receptor-positive (ER(+)) breast cancers. However, the development of endocrine resistance is the impediment for successful treatment. We aimed to explore the mechanisms of endocrine resistance and thera...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer
Autors principals: Yu, Xinfeng, Luo, Aiping, Liu, Yicong, Wang, Shuqing, Li, Ye, Shi, Wenna, Liu, Zhihua, Qu, Xianjun
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4678692/
https://ncbi.nlm.nih.gov/pubmed/26666173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-015-0480-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars